Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases

LI Zechao; ZHOU Yong; LUO Shiqiao

doi:10.3971/j.issn.1000-8578.2015.02.012

Cancer Research on Prevention and Treatment > 2015 > 42(02): 154-158. > DOI: 10.3971/j.issn.1000-8578.2015.02.012

LI Zechao, ZHOU Yong, LUO Shiqiao. Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 154-158. DOI: 10.3971/j.issn.1000-8578.2015.02.012

Citation:

PDF (1672 KB)

Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

More Information

Received Date: May 12, 2014
Revised Date: June 22, 2014

Graphical Abstract

Abstract

Abstract

Objective To analyze the clinical features of pancreatic cancer patients with liver metastasis and multimodality treatments, and to explore the impact of multimodality treatments on the prognosis of pancreatic cancer patients. Methods We retrospectively analyzed 64 pancreatic cancer patients with liver metastasis hospitalized in The First Affiliated Hospital of Chongqing Medical University from January 2009 to January 2012. Prognostic factors in clinical features and multimodality treatments were analyzed by Kaplan-Meier method and Cox regression model with SPSS19.0 software. Results The median survival time (MST) was 4 month. 6-month, 1-year and 2-year overall survival (OS) were 39.1%, 21.9% and 7.8% respectively. Univariate analysis revealed that there were significant differences in age, pain, anorexia, CA19-9, ALT and GGT levels, surgery, chemotherapy embolism/ transarterial chemotherapy, active treatment and multi-disciplinary treatment. Multivariate analysis showed that extrahepatic metastasis, pain, CA19-9, active treatment, surgery, chemotherapy embolism/transarterial chemotherapy and multi-disciplinary treatment were closely related to the survival and prognosis of patients. Conclusion In pancreatic cancer patients with liver metastases, pain, CA19-9≥1 000 u/ml and extrahepatic metastases at diagnosis are adverse prognostic factors. Active treatment, surgery, chemotherapy embolism/transarterial chemotherapy and multi-disciplinary treatment could improve the quality of life and prolong the survival time of pancreatic cancer patients with liver metastases.
- Pancreatic cancer,
- Liver metastasis,
- Multimodality treatment

FullText(HTML)

References (21)

References

[1]	Liu FY, Wang MQ, Duan F, et al. Hepatic artery chemoembolization in patients with liver metastasis from pancreatic carcinoma[J]. Zhongguo Zhong Liu Lin Chuang, 2012, 39(6): 331-5. [刘凤永,王茂强,段峰,等. 胰腺癌肝转移的介入治疗[J].中国肿瘤临床,2012,39(6):331-5.]
[2]	Katopodis O, Souglakos J, Stathopoulos E, et al. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) [J]. Cancer Chemother Pharmacol, 2014, 74(2):333-40.
[3]	Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges [J]. Nat Rev Clin Oncol, 2010, 7( 3):163-72.
[4]	Tas F, Sen F, Keskin S, et al. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival [J]. Mol Clin Oncol, 2013(1):788-92.
[5]	Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors of unresectable pancreatic cancer[J]. J Clin Gastroenterol, 2008, 42 (1):86-91.
[6]	Liu LX, Ji W, Wang JH, et al. A retrospective analysis on survival factors of transarterial chemoembolization for patients of pancreatic carcinoma with liver metastasis [J]. Fu Dan Xue Bao(Yi Xue Ban), 2011, 38(2): 101-6.[刘凌晓, 姬巍, 王建华, 等. 胰腺癌肝转移患者综合性介入栓塞治疗生存情况的回顾性分析[J] 复旦学报（医学报）, 2011, 38(2):101-6.]
[7]	Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase i/ii trial [J]. J Clin Oncol, 2011, 29(34): 45 49-50.
[8]	Ouyang HQ, Huang JQ, Liu LM, et al. Clinical analysis of multimodality treatment for 164 cases of pancreatic cancer with liver metastases[C].The First TCM and Western Medicine Oncology Forum in 2009 by Doctors and Young and Middle-aged Clinicians, 2011: 211-3.[欧阳华强,黄建琴,刘鲁明,等.多学科综合治疗胰腺癌肝转164例临床分析[C].2009年首届全国中西医肿瘤博士及中青年医师论坛, 2011: 211-3.]
[9]	Zhao J, Hu Y, Liao Q, et al. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer[J]. World J Gastroenterol, 2014, 20(19): 5875-80.
[10]	Yang GY, Malik NK, Chandrasekhar R, et al. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer [J]. J Gastrointest Oncol, 2013, 4(4): 361-9.
[11]	Ni QX, Yu XR, Liu L. Discussion for the clinical definition of pancreatic cancer in China [J]. Zhongguo Ai Zheng Za Zhi, 2012, 22 (2):81-7.[倪泉兴, 虞先溶, 刘亮. 中国胰腺癌临床诊断标准的探讨[J] 中国癌症杂志, 2012, 22(2): 81-7.]
[12]	Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma [J]. Ann Surg Oncol, 2007, 14 (1): 118-27.
[13]	Lorente-Herce JM, Parra-Membrives P, Díaz-Gómez D. Increased survival after resection of pancreatic cancer liver metastases[J]. Cir Esp, 2013, 91(6): 390-2.
[14]	SK S, Burkert B, AM C, et al. Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy [J]. HPB Surg, 2010, 2010: 579672.
[15]	Azizi A, Naguib NN, Mbalisike E, et al. Liver metastases of pancreatic cancer : role of repeti tive transar ter ial chemoembolization (TACE) on tumor response and survival [J]. Pancreas, 2011, 40(8): 1271-5.
[16]	Klimant E, Markman M, Albu DM. Clinically meaningful response to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer [J]. Case Rep Oncol, 20 13, 6(1): 72-7.
[17]	Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer [J]. N Engl J Med, 20 11, 364(19): 1817-25.
[18]	Sung HY, Jung SE, Cho SH, et al. Long-term outcome of highintensity focused ultrasound in advanced pancreatic cancer [J]. Pancreas, 2011, 40(7): 1080-6.
[19]	De Jong MC, Farmell MB, Sclabs G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis [J]. Ann Surg, 20 10, 252(1):142-8.
[20]	Xia SA, Wang J, Che LP, et al. Clinical significance of threedimensional conformal technique treatment for locally advanced pancreatic cancer[J].Zhongguo Yi Yao Dao Bao, 2012, 9( 35):75-6,80.[夏士安, 王佳, 车莉萍, 等. 探讨三维适行放射治疗在晚期胰腺癌中的临床意义[J]. 中国医药导报, 2012, 9(35): 75 -6,80.]
[21]	Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma. The Mayo Clinic experience(1975-2005) [J]. J Clin Oncol, 2008, 26 (21) : 3511-6.

[1]	SUN Jiaqi, WANG Yudong. Treatment Strategy and Research Progress of Immune Microenvironment for Liver Metastasis of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(3): 203-209. DOI: 10.3971/j.issn.1000-8578.2024.23.0878
[2]	LUO Xi, YI Junlin. Progress on Multi-disciplinary Combined Therapy for Locally Advanced Hypopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 327-333. DOI: 10.3971/j.issn.1000-8578.2023.22.1296
[3]	WANG Zhihui, ZHANG Shuijun. Influence of Multidisciplinary Combined Therapy on Curative Effect of Liver Cancer Treatment[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 880-885. DOI: 10.3971/j.issn.1000-8578.2022.22.0036
[4]	REN Gang, XIA Tingyi, WANG Yingjie. How to Exert Role of Radiotherapy in Treatment of Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 989-993. DOI: 10.3971/j.issn.1000-8578.2021.21.0883
[5]	REN Qing, XIONG Ruihua, TIAN Xiurong, BAO Zhongping, TANG Xinyun, LUO Kepin. ¹²⁵I Seed Implantation Combined with Chemotherapy for Colorectal Cancer with Postoperative Liver Metastasis[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 653-656. DOI: 10.3971/j.issn.1000-8578.2014.06.032
[6]	WANG Hongwu. Multidisciplinary Treatment of Malignant Tracheal Stenosis——Beijing Expert Consensus[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 94-96. DOI: 10.3971/j.issn.1000-8578.2014.01.022
[7]	YUAN Dai-yue, GUO Zhong-ying, ZAO Ren, HUANG Bao-yu, MEI Guang-lin, ZHU Jian-wei. Establishment and Comparison of Colon Cancer Liver Metastasis Models in Nude Mice[J]. Cancer Research on Prevention and Treatment, 2011, 38(01): 28-30. DOI: 10.3971/j.issn.1000-8578.2011.01.008
[8]	ZHNAG Yong-gang. Relative Histopathologic Evaluation of Colorectal Cancer with Liver Metastasis[J]. Cancer Research on Prevention and Treatment, 2004, 31(10): 655-656. DOI: 10.3971/j.issn.1000-8578.2093
[9]	LI Ping, LI Zhao-shen, WANG Ya-jie. Comparative study of gemcitabine plus cisplatin and FLEP regimen in the treatment of advanced pancreatic cancer[J]. Cancer Research on Prevention and Treatment, 2002, 29(01): 71-72. DOI: 10.3971/j.issn.1000-8578.133
[10]	Hu siahra, . The Study of THP and ADM in the Multimodality Targeting Treatment in Patients with Primary Liver Cancer[J]. Cancer Research on Prevention and Treatment, 1998, 25(4): 247-248.

Cited By

Cited by

Periodical cited type(1)

刘艳春，贾儒渊，樊志慧，王朝凤，苏海燕，曹文娟，徐丹丹. 表皮生长因子受体在食管鳞状细胞癌组织中的表达及其临床意义. 临床误诊误治. 2024(10): 35-38+43 .

Other cited types(0)

Get Citation

PDF

XML

Article views (2115) PDF downloads (1177) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Contact Us

Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Contact Us

Export File

Citation

Format

Content